Mana.bio has developed an integrated experimental and machine-learning platform to design smarter, faster, and more precise lipid nanoparticle delivery formulations for nucleic acid- and genetic-medicine applications. The company focuses on creating protective LNP 'packages' that stabilize volatile RNA molecules for delivery into human cells. Its approach targets RNA-based therapies with potential applications across infectious diseases, cancers and single-gene disorders. Mana.bio emerged from stealth after several years of research and announced its commercial launch alongside scientific papers it planned to present. The startup announced a $19.5 million seed financing and said it will continue advancing drug-discovery and development despite the wartime situation in Israel. CEO and co-founder Yogev Debbi led the announcement and emphasized the company's commitment to partners and patients.

Total raised

$20M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2023